Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer’s disease
Open Access
- 4 October 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 14, 949361
Abstract
Alzheimer’s diseaseis a progressive neurodegenerative disorder characterized histologically in postmortem human brains by the presence of dense protein accumulations known as amyloid plaques and tau tangles. Plaques and tangles develop over decades of aberrant protein processing, post-translational modification, and misfolding throughout an individual’s lifetime. We present a foundation of evidence from the literature that suggests chronic stress is associated with increased disease severity in Alzheimer’s patient populations. Taken together with preclinical evidence that chronic stress signaling can precipitate cellular distress, we argue that chronic psychological stress renders select circuits more vulnerable to amyloid- and tau- related abnormalities. We discuss the ongoing investigation of systemic and cellular processes that maintain the integrity of protein homeostasis in health and in degenerative conditions such as Alzheimer’s disease that have revealed multiple potential therapeutic avenues. For example, the endogenous cannabinoid system traverses the central and peripheral neural systems while simultaneously exerting anti-inflammatory influence over the immune response in the brain and throughout the body. Moreover, the cannabinoid system converges on several stress-integrative neuronal circuits and critical regions of the hypothalamic-pituitary-adrenal axis, with the capacity to dampen responses to psychological and cellular stress. Targeting the cannabinoid system by influencing endogenous processes or exogenously stimulating cannabinoid receptors with natural or synthetic cannabis compounds has been identified as a promising route for Alzheimer’s Disease intervention. We build on our foundational framework focusing on the significance of chronic psychological and cellular stress on the development of Alzheimer’s neuropathology by integrating literature on cannabinoid function and dysfunction within Alzheimer’s Disease and conclude with remarks on optimal strategies for treatment potential.Keywords
Funding Information
- National Institutes of Health
This publication has 301 references indexed in Scilit:
- Norepinephrine Drives Persistent Activity in Prefrontal Cortex via Synergistic α1 and α2 AdrenoceptorsPLOS ONE, 2013
- Norepinephrine: A Neuromodulator That Boosts the Function of Multiple Cell Types to Optimize CNS PerformanceNeurochemical Research, 2012
- Hostility and Cellular Aging in Men from the Whitehall II CohortBiological Psychiatry, 2012
- Characterization of cannabinoid-1 receptors in the locus coeruleus: Relationship with mu-opioid receptorsBrain Research, 2010
- Beta-Amyloid Deposition and the Aging BrainNeuropsychology Review, 2009
- Synaptic Depression and Aberrant Excitatory Network Activity in Alzheimer’s Disease: Two Faces of the Same Coin?NeuroMolecular Medicine, 2009
- Calpain-Mediated Signaling Mechanisms in Neuronal Injury and NeurodegenerationMolecular Neurobiology, 2008
- Repeated stress alters dendritic spine morphology in the rat medial prefrontal cortexJournal of Comparative Neurology, 2007
- Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortexBrain Research, 2007
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991